Free Cash Flow (Quarterly) Chart

View Free Cash Flow (Quarterly) for HIND.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow (Quarterly) Chart
Start Trial

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 -0.9037M
March 31, 2026 -1.436M
December 31, 2025 -1.478M
September 30, 2025 4.342M
June 30, 2025 -0.3063M
March 31, 2025 -0.2035M
December 31, 2024 -0.003M
September 30, 2024 2.817M
June 30, 2024 -1.357M
March 31, 2024 -2.072M
December 31, 2023 -2.457M
September 30, 2023 -2.78M
June 30, 2023 -6.698M
March 31, 2023 -5.068M
December 31, 2022 -2.908M
September 30, 2022 -5.306M
June 30, 2022 -6.434M
March 31, 2022 -7.385M
December 31, 2021 -3.493M
September 30, 2021 -7.889M
Date Value
June 30, 2021 -2.265M
March 31, 2021 -2.08M
December 31, 2020 -1.922M
September 30, 2020 -1.124M
June 30, 2020 -0.754M
March 31, 2020 -5.14M
December 31, 2019 -5.029M
September 30, 2019 -4.013M
June 30, 2019 -4.357M
March 31, 2019 -9.661M
December 31, 2018 -5.83M
September 30, 2018 -5.503M
June 30, 2018 -8.421M
March 31, 2018 -10.96M
December 31, 2017 -9.336M
September 30, 2017 -7.364M
June 30, 2017 -6.233M
March 31, 2017 -8.734M
December 31, 2016 -5.868M

Free Cash Flow Definition

Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
Cardiac Biotech Solutions, Inc. -0.1918M
Anika Therapeutics, Inc. -2.133M
Enovis Corp. 31.14M
Edwards Lifesciences Corp. 585.00M
Perspective Therapeutics, Inc. -34.87M